Local Consolidative Therapy Does Not Improve Survival After Dual Immunotherapy in Metastatic NSCLC

Local consolidative therapy (LCT) added after induction treatment with the immune‑checkpoint inhibitors nivolumab and ipilimumab did not extend overall survival (OS) or progression‑free survival (PFS) in patients with metastatic non‑small cell lung cancer (NSCLC), including those with oligometastatic disease, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC). The study, which evaluated patients who received standard immunotherapy followed by either surgical resection, stereotactic body radiotherapy, or other local ablative approaches, found no statistically significant improvement in survival outcomes compared with immunotherapy alone.

The data were derived from a multicenter cohort of metastatic NSCLC patients, encompassing both oligometastatic and polymetastatic cases. While LCT has shown promise in select malignancies, the IASLC presentation indicated that, in this setting, the addition of local treatment after systemic immunotherapy did not confer a measurable benefit in either OS or PFS. The investigators highlighted that these results suggest the limited role of LCT in the context of contemporary immunotherapy regimens for metastatic NSCLC.

These findings underscore the need for continued research into optimal sequencing and combination strategies for metastatic NSCLC. Clinicians and researchers will likely focus on identifying biomarkers or patient subgroups that might derive benefit from local interventions, while continuing to refine systemic immunotherapy approaches to improve long‑term outcomes.